{"ModuleTitle": "Company Description", "CompanyName": "Pacific Biosciences of California, Inc.", "Symbol": "PACB", "Address": "1305 O'BRIEN DRIVE, MENLO PARK, California, 94025, United States of America", "Phone": "650-521-8000", "Industry": "Biotechnology: Laboratory Analytical Instruments", "Sector": "Capital Goods", "Region": "North America", "CompanyDescription": "On November 1, 2018, we entered into an Agreement and Plan of Merger (as\r\namended, the \"Merger Agreement\") with Illumina, Inc. (\"Illumina\") and FC Ops\r\nCorp., a wholly owned subsidiary of Illumina (\"Merger Subsidiary\"). We, Illumina\r\nand Merger Subsidiary entered into Amendment No. 1 to the Merger Agreement  (the\r\n\"Amendment\") on September 25, 2019. The Amendment, among other things, extended\r\nthe End Time (as defined in the Merger Agreement) to December 31, 2019.\r\nAdditionally, Illumina had until December 18, 2019 to exercise its unilateral\r\nright to extend the End Time to March 31, 2020. In addition, the Amendment\r\nprovided that Illumina would make payments to us of $6.0 million on or before\r\neach of October 1, 2019, November 1, 2019 and December 2, 2019.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f28%2f0001299130-20-000008.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Denis Zaccarin", "title": "Senior Vice President-Research & Development"}, {"name": "Jonas Korlach", "title": "Chief Scientific Officer"}, {"name": "Michael W. Hunkapiller", "title": "President, Chief Executive Officer & Director"}, {"name": "Stephen W. Turner", "title": "Chief Technology Officer"}, {"name": "Susan K. Barnes", "title": "Chief Financial Officer & Executive Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}